Back to Journals » Drug Design, Development and Therapy » Volume 7
Current and emerging pharmacological treatments for sarcoidosis: a review
Authors Beegle SH, Barba K, Gobunsuy R, Judson MA
Received 29 January 2013
Accepted for publication 9 March 2013
Published 12 April 2013 Volume 2013:7 Pages 325—338
DOI https://doi.org/10.2147/DDDT.S31064
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Scott H Beegle,1 Kerry Barba,2 Romel Gobunsuy,1 Marc A Judson1
1Division of Pulmonary and Critical Care Medicine, 2Department of Medicine, Albany Medical College, Albany, NY, USA
Abstract: The treatment of sarcoidosis is not standardized. Because sarcoidosis may never cause significant symptoms or organ dysfunction, treatment is not mandatory. When treatment is indicated, oral corticosteroids are usually recommended because they are highly likely to be effective in a relative short period of time. However, because sarcoidosis is often a chronic condition, long-term treatment with corticosteroids may cause significant toxicity. Therefore, corticosteroid sparing agents are often indicated in patients requiring chronic therapy. This review outlines the indications for treatment, corticosteroid treatment, and corticosteroid sparing treatments for sarcoidosis.
Keywords: pulmonary sarcoidosis, extrapulmonary sarcoidosis, treatment, drugs, corticosteroids
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.